196 related articles for article (PubMed ID: 8668202)
1. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.
Parry D; Peters G
Mol Cell Biol; 1996 Jul; 16(7):3844-52. PubMed ID: 8668202
[TBL] [Abstract][Full Text] [Related]
2. Mutations associated with familial melanoma impair p16INK4 function.
Ranade K; Hussussian CJ; Sikorski RS; Varmus HE; Goldstein AM; Tucker MA; Serrano M; Hannon GJ; Beach D; Dracopoli NC
Nat Genet; 1995 May; 10(1):114-6. PubMed ID: 7647780
[TBL] [Abstract][Full Text] [Related]
3. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.
FitzGerald MG; Harkin DP; Silva-Arrieta S; MacDonald DJ; Lucchina LC; Unsal H; O'Neill E; Koh J; Finkelstein DM; Isselbacher KJ; Sober AJ; Haber DA
Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8541-5. PubMed ID: 8710906
[TBL] [Abstract][Full Text] [Related]
5. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product/p16.
Wick ST; Dubay MM; Imanil I; Brizuela L
Oncogene; 1995 Nov; 11(10):2013-9. PubMed ID: 7478520
[TBL] [Abstract][Full Text] [Related]
7. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity.
Lilischkis R; Sarcevic B; Kennedy C; Warlters A; Sutherland RL
Int J Cancer; 1996 Apr; 66(2):249-54. PubMed ID: 8603820
[TBL] [Abstract][Full Text] [Related]
8. Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519).
Jadayel DM; Lukas J; Nacheva E; Bartkova J; Stranks G; De Schouwer PJ; Lens D; Bartek J; Dyer MJ; Kruger AR; Catovsky D
Leukemia; 1997 Jan; 11(1):64-72. PubMed ID: 9001420
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
Fåhraeus R; Laín S; Ball KL; Lane DP
Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
[TBL] [Abstract][Full Text] [Related]
10. New tumor suppressor may rival p53.
Marx J
Science; 1994 Apr; 264(5157):344-5. PubMed ID: 8153613
[No Abstract] [Full Text] [Related]
11. Biochemical characterization of p16INK4- and p18-containing complexes in human cell lines.
Ragione FD; Russo GL; Oliva A; Mercurio C; Mastropietro S; Pietra VD; Zappia V
J Biol Chem; 1996 Jul; 271(27):15942-9. PubMed ID: 8663131
[TBL] [Abstract][Full Text] [Related]
12. Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6.
Noh SJ; Li Y; Xiong Y; Guan KL
Cancer Res; 1999 Feb; 59(3):558-64. PubMed ID: 9973200
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
Fuxe J; Akusjärvi G; Goike HM; Roos G; Collins VP; Pettersson RF
Cell Growth Differ; 2000 Jul; 11(7):373-84. PubMed ID: 10939591
[TBL] [Abstract][Full Text] [Related]
14. A cell cycle regulator potentially involved in genesis of many tumor types.
Kamb A; Gruis NA; Weaver-Feldhaus J; Liu Q; Harshman K; Tavtigian SV; Stockert E; Day RS; Johnson BE; Skolnick MH
Science; 1994 Apr; 264(5157):436-40. PubMed ID: 8153634
[TBL] [Abstract][Full Text] [Related]
15. Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.
Ceha HM; Nasser I; Medema RH; Slebos RJ
Biochem Biophys Res Commun; 1998 Aug; 249(2):550-5. PubMed ID: 9712735
[TBL] [Abstract][Full Text] [Related]
16. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16.
Lukas J; Parry D; Aagaard L; Mann DJ; Bartkova J; Strauss M; Peters G; Bartek J
Nature; 1995 Jun; 375(6531):503-6. PubMed ID: 7777060
[TBL] [Abstract][Full Text] [Related]
17. p16 proteins from melanoma-prone families are deficient in binding to Cdk4.
Reymond A; Brent R
Oncogene; 1995 Sep; 11(6):1173-8. PubMed ID: 7566978
[TBL] [Abstract][Full Text] [Related]
18. Lack of germline CDK6 mutations in familial melanoma.
Shennan MG; Badin AC; Walsh S; Summers A; From L; McKenzie M; Goldstein AM; Tucker MA; Hogg D; Lassam N
Oncogene; 2000 Mar; 19(14):1849-52. PubMed ID: 10777219
[TBL] [Abstract][Full Text] [Related]
19. Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes.
Soufir N; Bressac-de Paillerets B; Desjardins L; Lévy C; Bombled J; Gorin I; Schlienger P; Stoppa-Lyonnet D
Br J Cancer; 2000 Feb; 82(4):818-22. PubMed ID: 10732752
[TBL] [Abstract][Full Text] [Related]
20. An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4.
Li J; Joo SH; Tsai MD
Biochemistry; 2003 Nov; 42(46):13476-83. PubMed ID: 14621993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
